ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda President and CEO will deliver a corporate presentation on Wednesday, May 28, 2008, at 9:00 a.m. Eastern Time.
The presentation will take place as part of the FBR Capital Markets 12th Annual Spring Investor Conference at the Grand Hyatt, New York, New York. Dr. Polymeropoulos' remarks will be available live on the Vanda Website, where it also will be archived for 30 days.
To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the website several minutes prior to the start of the live presentation.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, Fanapta(TM) (iloperidone), for which Vanda has recently submitted an NDA to the FDA, is a compound for the treatment of schizophrenia. Vanda's second product candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic primary insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.
CONTACT: Steven Shallcross, Chief Financial Officer of Vanda
Pharmaceuticals Inc., +1-240-599-4500, steven.shallcross@vandapharma.com
Web site: http://www.vandapharma.com/
